Researchers examine how far follicular lymphoma treatment has come, what limitations still remain, and where the management of the disease is headed.
Tafasitamab-cxix is a humanized Fc-modified monoclonal antibody that targets CD19 antigen on the surface of pre-B and mature B lymphocytes and on several B-cell malignancies, including DLBCL.
CD30 CAR-T cell treatment after lymphodepletion may produce antitumor activity without significant toxicity in relapsed or refractory Hodgkin lymphoma.
Researchers for the RELEVANCE study measured MRD in a subset of patients to compare the molecular response of patients receiving R2 vs R-chemo.
The FDA has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel; Kite Pharma) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.
A prospective NCTN PET-directed analysis aimed to eradicate the short- and long-term toxicities associated with RT in patients with limited-stage DLBCL.
Researchers studied the pros and cons of transplantation from different donor sources to enhance overall outcomes of allo-HSCT in adults with T-cell malignancies.
A retrospective study found similar efficacy and toxicity outcomes among patients with refractory DLBCL who were treated with axi-cel outside of trial inclusion criteria.
The authors noted that these findings should be seen as a reference for the mutational landscape in MCL at baseline and at disease progression after treatment.
Because primary pancreatic lymphoma is a rare disease, optimal diagnostic and therapeutic protocols have not yet been established.
A clinical trial suggests efficacy and a manageable adverse event profile with selinexor for the treatment of relapsed or refractory DLBCL.
Flow cytometry may provide an efficient, sensitive, and specific tool for the differential diagnosis of breast implant–associated ALCL, but a cell block may be able to answer additional questions about the disease.
AALL0434, one of the largest prospective studies of T-LL, resulted in successful disease-free and overall survival outcomes.
For pediatric high-risk B-cell NHL, adding rituximab to standard LMB chemotherapy prolongs event-free and overall survival but may increase adverse events.
The FDA has granted accelerated approval of Xpovio® (selinexor; Karyopharm) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.
High-intensity RIC-NMAC regimen Flu-Mel140, may be linked to higher nonrelapse mortality in patients with NHL undergoing allogeneic transplantation.
Tazverik, a methyltransferase inhibitor, is already indicated for the treatment of patients aged ≥16 years with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Researchers conducted a multicenter, retrospective analysis of outcomes for 1360 patients who were treated with RT with or without nonanthracycline-based CT.
Dose-adjusted EPOCH-R resulted in higher tolerance and efficacy among adults with Burkitt lymphoma.
Even among those with more comorbidities, safety, efficacy of treatment remained.
Researchers compared the efficacy and nephrotoxicity of R-DHAP vs R-DHAOx among patients treated for NHL between 2007 and 2014.
SEER analysis reveals age, Ann Arbor stage, and chemotherapy as critical factors affecting prognosis in patients with primary cardiac lymphoma.
Nivolumab-based first-line treatment may result in high remission and progression-free survival rates in early-stage unfavorable classic Hodgkin lymphoma.
Hypercalcemia is not uncommon in patients with de novo diffuse large B-cell lymphoma and may be linked to a higher risk for other adverse events.
Combined targeted agents with immune regulators and chimeric antigen receptor cell–based therapies may improve overall survival for patients with PTCL.
Clonal hematopoiesis of indeterminate origin has been defined as the presence of somatic mutations in hematopoietic stem cells at a variant gene frequency of more than 2%.
Researchers oulined changes in diagnostics, surveillance, and treatment practices that could lead to better outcomes for patients with NHL in sub-Saharan Africa.
Researchers found that dose-adjusted (DA-) etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) for B-cell lymphomas can be administered safely in the outpatient setting and that outpatient administration was associated with significant savings relative to inpatient administration. Wenhui Li, PharmD, of the H. Lee Moffitt Cancer Center in Tampa, Florida, and colleagues published their findings in…
There is clinical and real-world evidence that indicates some patients do not complete treatment for reasons other than lack of response.
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
Researchers conducted a 2-year safety and efficacy follow-up analysis to determine whether long-term data support the initial toxicity findings.
While HLA-identical sibling or unrelated donors were previously critical for successful transplantation, increased genomic heterogeneity across populations have heightened the need for alternatives.
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
Patients with LPL or WM had a 30% increased risk for death due to noncancer causes compared with the general population.
Stable disease or progression compared with complete response was found to be predictive of overall survival in patients receiving rituximab-primary treatment.
Half of responses with urelumab monotherapy were found to occur at a dosage above the maximum tolerated dose.
Patients with relapsed/refractory diffuse large B-cell lymphoma who responded to tisagenlecleucel also had improved health-related quality of life outcomes.
Overall survival, progression-free survival, and nonrelapse mortality were found to be similar in patients receiving BEAM conditioning with or without rituximab.
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Patients receiving pixantrone plus rituximab and patients receiving gemcitabine plus rituximab experienced similar progression-free survival.
Despite improvements in treatment of CNS lymphoma, median age of people who develop the disease is increasing. Nearly three-quarters of patients included in this population-based study were 60 years or older.
A deepened response following therapy with a regimen containing rituximab was associated with improved progression-free survival.
Bendamustine-based first-line chemotherapy was associated with fewer hospitalizations and fewer toxic events compared with cyclophosphamide-based regimens.